Psychedelic Business Spotlight – July 1
This week in psychedelic stock news: MindMed downplays delisiting fears; Red Light Holland teams with Wiz Khalifa; Field Trip shareholders approve company split; and more!
MindMed
MindMed Reassures Investors over Nasdaq Delisting Fears
In a Reddit AMA, MindMed CEO Robert Barrow says Nasdaq delisting is not “a risk of any sort.”
This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.
Psychedelic Business Spotlight – June 10
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed’s stock is removed from an index; and more!
Does MDMA Reduce Fear? New Study Has Implications for PTSD Treatment
Using a measurement tool called the SCR, researchers found that combining MDMA with fear extinction learning and recall therapy significantly reduced the fear felt by study participants, as compared to the placebo. This may have big implications for how we treat PTSD.
Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock Analysis
Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.
Psychedelic Business Spotlight – May 13
This week in psychedelic business news: Beckley Retreats set launch; another shark swims into the psychedelics industry; and MindMed shares promising LSD study results.
MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success
Researchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
Why Wednesday Will Be Biggest Day of 2022 for Psychedelic Investors
Psychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.
Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?
Our resident Psychedelic Investor James Hallifax wonders if the “Shark Tank” star’s prediction makes financial sense.
End of content
End of content